Stockreport

NodThera's NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk [Yahoo! Finance]

Blue Owl Capital Inc. Class A  (OWL) 
PDF Brain-penetrant NLRP3 inflammasome inhibitor demonstrates highly significant and rapid reduction of key inflammatory marker CRP compared to placebo Reductions in mult [Read more]